Always good to see experts making comments like the one I have highlighted .... and as someone else mentioned, it is great to see Mesoblast openly name ruxolitinib as one of the poorer performing other therapies compared with Remestemcel-L in the review .....
Ann: Remestemcel-L Improves Survival in High-Risk Acute GvHD, page-24
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
0.050(4.59%) |
Mkt cap ! $1.301B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.14 | $1.08 | $6.654M | 5.972M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1330 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 171164 | 10 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |